Simulating molecular mechanisms of the MDM2-mediated regulatory interactions: A conformational selection model of the MDM2 lid dynamics

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Verkhivker, Gennady M ^a,b  

^a CHAPMAN UNIVERSITY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MDM2; PROTEIN P53;

ARTICLE; BINDING AFFINITY; BINDING SITE; CALCULATION; CHEMICAL MODIFICATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; HYDROGEN BOND; MOLECULAR DOCKING; MUTATION; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SIMULATION; THERMODYNAMICS;

AMINO ACID SEQUENCE; APOPROTEINS; MOLECULAR DYNAMICS SIMULATION; MOLECULAR MIMICRY; MOLECULAR SEQUENCE DATA; MUTATION; PHOSPHORYLATION; PHOSPHOSERINE; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN INTERACTION MAPS; PROTEIN STABILITY; PROTO-ONCOGENE PROTEINS C-MDM2; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84864023880     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040897     Document Type: Article

References (139)

1. Lane DP, (1992) Cancer. p53, guardian of the genome. 1358: 15-16 http://www.ncbi.nlm.nih.gov/pubmed?term=p53%2C%20guardian%20of%20the%20genome.%20DP%2C%20Lane- #.
2. Levine AJ, (1997) p53, the cellular gatekeeper for growth and division Cell 88: 323-331.
3. Römer L, Klein C, Dehner A, Kessler H, Buchner J, (2006) p53-a natural cancer killer: structural insights and therapeutic concepts. Angew Chem Int Ed Engl 45: 6440-6460.
4. Picksley SM, Lane DP, (1993) The p53-MDM2 autoregulatory feedbac loop-a paradigm for the regulation of growth control by p53? BioEssays 15: 689-690.
5. Momand J, Zambetti GP, Olson DC, GeorgeD, Levine AJ, (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69: 1237-1245.
6. Honda R, Tanaka H, Yasuda H, (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420: 25-27.
7. Haupt Y, Maya R, Kazaz A, Oren M, (1997) MDM2 promotes the rapid degradation of p53. Nature 387: 296-299.
8. Maki CG, (1999) Oligomerization is required for p53 to be efficiently ubiquitinated by MDM2. J Biol Chem 274: 16531-16535.
9. Shirangi TR, Zaika A, Moll UM, (2002) Nuclear degradation of p53 occurs during down-regulation of the p53 response after DNA damage. FASEB J 16: 420-422.
10. Chen J, Lin J, Levine AJ, (1995) Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol Med 1: 142-152.
11. Roth J, Dobbelstein M, Freedman DA, Shenk T, Levine AJ, (1998) Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein. EMBO J 17: 554-564.
12. Chen J, Marechal V, Levine AJ, (1993) Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 13: 4107-4114.
13. Stommel JM, Wahl GM, (2005) New twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle 4: 411-417.
14. Vousden KH, Prives C, (2005) P53 and prognosis: new insights and further complexity. Cell 120: 7-10.
15. Bond GL, Hu W, Levine AJ, (2005) MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets 5: 3-8.
16. Romer L, Klein C, Dehner A, Kessler H, Buchner J, (2006) p53-a natural cancer killer: structural insights and therapeutic concepts. Angew Chem Int Ed Engl 45: 6440-6460.
17. Vazquez A, Bond EE, Levine AJ, Bond GL, (2008) The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov 7: 979-987.
18. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP, (2009) Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9: 862-873.
19. Manfredi JJ, (2010) The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev 24: 1580-1589.
20. Vucic D, Dixit VM, Wertz IE, (2011) Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death. Nat Rev Mol Cell Biol 12: 439-452.
21. Brooks CL, Gu W, (2011) p53 regulation by ubiquitin. FEBS Lett 585: 2803-2809.
22. Shen H, Maki CG, (2011) Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr Pharm Des 17: 560-568.
23. MacLaine NJ, Hupp TR, (2011) How phosphorylation controls p53. Cell Cycle 10: 916-921.
24. Cheok CF, Verma CS, Baselga J, Lane DP, (2011) Translating p53 into the clinic. Nat Rev Clin Oncol 8: 25-37.
25. Brown CJ, Cheok CF, Verma CS, Lane DP, (2011) Reactivation of p53: from peptides to small molecules. Trends Pharmacol Sci 32: 53-62.
26. Mayo LD, Turchi JJ, Berberich SJ, (1997) Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res 57: 5013-5016.
27. Appella E, Anderson CW, (2001) Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem 268: 2764-2772.
28. Wang Z, Li B, (2010) Mdm2 links genotoxic stress and metabolism to p53. Protein Cell 1: 1063-1072.
29. Henning W, Rohaly G, Kolzau T, Knippschild U, Maacke H, et al. (1997) MDM2 is a target of simian virus 40 in cellular transformation and during lytic infection. J Virol 71: 7609-7618.
30. Hay TJ, Meek DW, (2000) Multiple sites of in vivo phosphorylation in the MDM2 oncoprotein cluster within two important functional domains. FEBS Lett 478: 183-186.
31. Mayo LD, Donner DB, (2001) A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci USA 98: 11598-11603.
32. Meek DW, Knippschild U, (2003) Posttranslational modification of MDM2. Mol Cancer Res 1: 1017-1026.
33. Kruse JP, Gu W, (2009) Modes of p53 regulation. Cell 137: 609-622.
34. Teufel DP, Bycroft M, Fersht AR, (2009) Regulation by phosphorylation of the relative affinities of the N-terminal transactivation domains of p53 for p300 domains and Mdm2. Oncogene 28: 2112-2118.
35. Meek DW, Hupp TR, (2010) The regulation of MDM2 by multisite phosphorylation opportunities for molecular-based intervention to target tumours? Semin Cancer Biol 20: 19-28.
36. Wade M, Wang YV, Wahl GM, (2010) The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 20: 299-309.
37. Inuzuka H, Fukushima H, Shaik S, Wei W, (2010) Novel insights into the molecular mechanisms governing Mdm2 ubiquitination and destruction. Oncotarget 1: 685-690.
38. MacLaine NJ, Hupp TR, (2011) How phosphorylation controls p53. Cell Cycle 10: 916-921.
39. Shieh SY, Ikeda M, Taya Y, Prives C, (1997) DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91: 325-334.
40. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C, (2000) The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 14, 289-300.
41. Chao C, Hergenhahn M, Kaeser MD, Wu Z, Saito S, et al. (2003) Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J Biol Chem 278: 41028-41033.
42. Craig AL, Burch L, Vojtesek B, Mikutowska J, Thompson A, et al. (1999) Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochem J 342: 133-141.
43. Blattner C, Tobiasch E, Litfen M, Rahmsdorf HJ, Herrlich P, (1999) DNA damage induced p53 stabilization: no indication for an involvement of p53 phosphorylation. Oncogene 18: 1723-1732.
44. Jackson MW, Agarwal MK, Agarwal ML, Agarwal A, Stanhope-Baker P, et al. (2004) Limited role of N-terminal phosphoserine residues in the activation of transcription by p53. Oncogene 23: 4477-4487.
45. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, et al. (1996) Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 274: 948-953.
46. Böttger A, Böttger V, Garcia-Echeverria C, Chène P, Hochkeppel HK, et al. (1997) Molecular characterization of the hdm2-p53 interaction. J Mol Biol 269: 744-756.
47. Böttger V, Böttger A, Garcia-Echeverria C, Ramos YF, van der Eb AJ, (1999) Comparative study of the p53-mdm2 and p53-MDMX interfaces. Oncogene 18: 189-199.
48. Freedman DA, Epstein CB, Roth JC, Levine AJ, (1997) A genetic approach to mapping the p53 binding site in the MDM2 protein. Mol Med 3: 248-259.
49. Jimenez GS, Khan SH, Stommel JM, Wahl GM, (1999) p53 regulation by post-translational modification and nuclear retention in response to diverse stresses. Oncogene 18: 7656-7665.
50. Craig AL, Burch L, Vojtesek B, Mikutowska J, Thompson A, et al. (1999) Novel phosphorylation sites of human tumor suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 protein are modified in human cancers. Biochem J 342: 133-141.
51. Sakaguchi K, Saito S, Higashimoto Y, Roy S, Anderson CW, (2000) Damage?mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase: Effect on Mdm2 binding. J Biol Chem 275: 9278-9283.
52. Lai Z, Auger KR, Manubay CM, Copeland RA, (2000) Thermodynamics of p53 binding to hdm2(1-126): effects of phosphorylation and p53 peptide length. Arch Biochem Biophys 381: 278-284.
53. Schon O, Friedler A, Bycroft M, Freund SM, Fersht AR, (2002) Molecular mechanism of the interaction between MDM2 and p53. J Mol Biol 323: 491-501.
54. Schon O, Friedler A, Freund S, Fersht AR, (2004) Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes. J Mol Biol 336: 197-202.
55. McCoy MA, Gesell JJ, Senior MM, Wyss DF, (2003) Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation. Proc Natl Acad Sci USA 100: 1645-1648.
56. Uhrinova S, Uhrin D, Powers H, Watt K, Zheleva D, et al. (2005) Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J Mol Biol 350: 587-598.
57. Showalter SA, Bruschweiler-Li L, Johnson E, Zhang F, Bruschweiler R, (2008) Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft. J Am Chem Soc 130: 6472-6478.
58. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, et al. (2004) In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844-848.
59. Vassilev LT, (2004) Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 3: 419-421.
60. Fry DC, Emerson SD, Palme S, Vu BT, Liu CM, et al. (2004) NMR structure of a complex between MDM2 and a small molecule inhibitor. J Biomol NMR 30: 163-173.
61. Worrall EG, Wawrzynow B, Worrall L, Walkinshaw M, Ball KL, et al. (2009) Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudosubstrate motif. J Chem Biol 2: 113-129.
62. Worrall EG, Worrall L, Blackburn E, Walkinshaw M, Hupp TR, (2010) The effects of phosphomimetic lid mutation on the thermostability of the N-terminal domain of MDM2. J Mol Biol 398: 414-428.
63. Zhan C, Varney K, Yuan W, Zhao L, Lu W, (2012) Interrogation of MDM2 phosphorylation in p53 activation using native chemical ligation: The functional role of Ser17 phosphorylation in MDM2 reexamined. J Am Chem Soc 134: 6855-6864.
64. Fasan R, Dias RL, Moehle K, Zerbe O, Obrecht D, et al. (2006) Structure-activity studies in a family of beta-hairpin protein epitope mimetic inhibitors of the p53-HDM2 protein-protein interaction Chembiochem 7: 515-526.
65. Sakurai K, Schubert C, Kahne D, (2006) Crystallographic analysis of an 8-mer p53 peptide analogue complexed with MDM2 J Am Chem Soc 128: 11000-11001.
66. Popowicz GM, Czarna A, Rothweiler U, Szwagierczak A, Krajewski M, (2007) Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle 6: 2386-2392.
67. Popowicz GM, Czarna A, Holak TA, (2008) Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain. Cell Cycle 7(15): 2441-2443.
68. Kallen J, Goepfert A, Blechschmidt A, Izaac A, Geiser M, et al. (2009) Crystal structures of human MdmX (HdmX) in complex with p53 peptide analogues reveal surprising conformational Changes. J Biol Chem 284: 8812-8821.
69. Pazgier M, Liu M, Zou G, Yuan W, Li C, et al. (2009) Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX. Proc Natl Acad Sci U S A 106: 4665-4670.
70. Czarna A, Popowicz GM, Pecak A, Wolf S, Dubin G, (2009) High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx. Cell Cycle 8: 1176-1184.
71. Li C, Pazgier M, Liu M, Lu WY, Lu W, (2009) Apamin as a template for structure-based rational design of potent peptide activators of p53. Angew Chem Int Ed Engl 48: 8712-8715.
72. Phan J, Li Z, Kasprzak A, Li B, Sebti S, (2010) Structure-based design of high affinity peptides inhibiting the interaction of p53 with MDM2 and MDMX. J Biol Chem 285: 2174-2183.
73. Li C, Pazgier M, Li C, Yuan W, Liu M, (2010) Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions. J Mol Biol 398: 200-213.
74. Liu M, Pazgier M, Li C, Yuan W, Li C, et al. (2010) A left-handed solution to peptide inhibition of the p53-MDM2 interaction.Angew Chem Int Ed Engl 49: 3649-3652.
75. Baek S, Kutchukian PS, Verdine GL, Huber R, Holak TA, et al. (2012) Structure of the stapled p53 peptide bound to Mdm2. J Am Chem Soc 134: 103-106.
76. Grasberger BL, Lu T, Schubert C, Parks DJ, Carver TE, et al. (2005) Discovery and cocrystal structure of benzodiazepinedione HDM2 antagonists that activate p53 in cells. J Med Chem 48: 909-912.
77. Allen JG, Bourbeau MP, Wohlhieter GE, Bartberger MD, Michelsen K, et al. (2009) Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction. J Med Chem. 52: 7044-7053.
78. Popowicz GM, Czarna A, Wolf S, Wang K, Wang W, et al. (2010) Structures of low molecular weight inhibitors bound to MDMX and MDM2 reveal new approaches for p53-MDMX/MDM2 antagonist drug discovery. Cell Cycle 9: 1104-1111.
79. Liu M, Li C, Pazgier M, Li C, Mao Y, et al. (2010) D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms. Proc Natl Acad Sci U S A 107: 14321-14326.
80. Huang Y, Wolf S, Koes D, Popowicz GM, Camacho CJ, et al. (2012) Exhaustive fluorine scanning toward potent p53-Mdm2 antagonists. ChemMedChem 7: 49-52.
81. Huo S, Massova I, Kollman PA, (2002) Computational alanine scanning of the 1:1 human growth hormone-receptor complex. J Comput Chem 23: 15-27.
82. Zhong H, Carlson HA, (2005) Computational studies and peptidomimetic design for the human p53-MDM2 complex. Proteins 58: 222-34.
83. Lu F, Chi SW, Kim DH, Han KH, Kuntz ID, et al. (2006) Proteomimetic libraries: design, synthesis, and evaluation of p53-MDM2 interaction inhibitors. J Comb Chem 8: 315-325.
84. Sood VD, Baker D, (2006) Recapitulation and design of protein binding peptide structures and sequences. J Mol Biol 357: 917-927.
85. Espinoza-Fonseca LM, Trujillo-Ferrara JG, (2006) Transient stability of the helical pattern of region F19-L22 of the N-terminal domain of p53: a molecular dynamics simulation study. Biochem Biophys Res Commun 343: 110-116.
86. Espinoza-Fonseca LM, Trujillo-Ferrara JG, (2006) Conformational changes of the p53-binding cleft of MDM2 revealed by molecular dynamics simulations. Biopolymers 83: 365-373.
87. Lee HJ, Srinivasan D, Coomber D, Lane DP, Verma CS, (2007) Modulation of the p53-MDM2 interaction by phosphorylation of Thr18: a computational study. Cell Cycle 6: 2604-2611.
88. Brown CJ, Srinivasan D, Jun LH, Coomber D, Verma CS, et al. (2008) The electrostatic surface of MDM2 modulates the specificity of its interaction with phosphorylated and unphosphorylated p53 peptides. Cell Cycle 7: 608-610.
89. Dastidar SG, Lane DP, Verma CS, (2009) Modulation of p53 binding to MDM2: computational studies reveal important roles of Tyr100. BMC Bioinformatics 10: S6.
90. Dastidar SG, Raghunathan D, Nicholson J, Hupp TR, Lane DP, et al. (2011) Chemical states of the N-terminal "lid" of MDM2 regulate p53 binding: simulations reveal complexities of modulation. Cell Cycle 10: 82-89.
91. Dastidar SG, Lane DP, Verma CS, (2008) Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2. J Am Chem Soc 130: 13514-13515.
92. Joseph TL, Madhumalar A, Brown CJ, Lane DP, Verma CS, (2010) Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies. Cell Cycle 9: 1167-1181.
93. Bowman AL, Nikolovska-Coleska Z, Zhong H, Wang S, Carlson HA, (2007) Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models. J Am Chem Soc 129: 12809-12814.
94. Ding Y, Mei Y, Zhang JZ, (2008) Quantum mechanical studies of residue-specific hydrophobic interactions in p53-MDM2 binding. J Phys Chem B 112: 11396-11401.
95. Madhumalar A, Lee HJ, Brown CJ, Lane D, Verma C, (2009) Design of a novel MDM2 binding peptide based on the p53 family. Cell Cycle (8): 2828-2836.
96. Grässlin A, Amoreira C, Baldridge KK, Robinson JA, (2009) Thermodynamic and computational studies on the binding of p53-derived peptides and peptidomimetic inhibitors to HDM2. Chembiochem 10: 1360-1368.
97. Kalid O, Ben-Tal N, (2009) Study of MDM2 binding to p53-analogues: affinity, helicity, and applicability to drug design. J Chem Inf Model 49: 865-876.
98. Hu G, Wang D, Liu X, Zhang Q, (2010) A computational analysis of the binding model of MDM2 with inhibitors. J Comput Aided Mol Des 24: 687-697.
99. Barakat K, Mane J, Friesen D, Tuszynski J, (2010) Ensemble-based virtual screening reveals dual-inhibitors for the p53-MDM2/MDMX interactions. J Mol Graph Model 28: 555-568.
100. Chen J, Wang J, Xu B, Zhu W, Li G, (2011) Insight into mechanism of small molecule inhibitors of the MDM2-p53 interaction: molecular dynamics simulation and free energy analysis. J Mol Graph Model 30: 46-53.
101. Lu SY, Jiang YJ, Zou JW, Wu TX, (2011) Molecular modeling and molecular dynamics simulation studies on pyrrolopyrimidine-based α-helix mimetic as dual inhibitors of MDM2 and MDMX. J Mol Graph Model 30: 167-178.
102. Chen J, Zhang D, Zhang Y, Li G, (2012) Computational studies of difference in binding modes of peptide and non-peptide inhibitors to MDM2/MDMX based on molecular dynamics simulations. Int J Mol Sci 13: 2176-2195.
103. Brown CJ, Dastidar SG, Quah ST, Lim A, Chia B, et al. (2011) C-terminal substitution of MDM2 interacting peptides modulates binding affinity by distinctive mechanisms. PLoS One 6: e24122.
104. Shangary S, Wang S, (2009) Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol. 49: 223-241.
105. Lauria A, Tutone M, Ippolito M, Pantano L, Almerico AM, (2010) Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules. Curr Med Chem 17: 3142-3154.
106. Csermely P, Palotai R, Nussinov R, (2010) Induced fit, conformational selection and independent dynamic segments: an extended view of binding events. Trends Biochem Sci 35: 539-546.
107. Changeux JP, (2012) Allostery and the Monod-Wyman-Changeux model after 50 years. Annu Rev Biophys 41: 103-133.
108. Lange OF, Lakomek NA, Farès C, Schröder GF, Walter KF, et al. (2008) Recognition dynamics up to microseconds revealed from an RDC-derived ubiquitin ensemble in solution. Science 320: 1471-1475.
109. Eisenmesser EZ, Millet O, Labeikovsky W, Korzhnev DM, Wolf-Watz M, et al. (2005) Intrinsic dynamics of an enzyme underlies catalysis. Nature 438: 117-121.
110. Tang C, Schwieters CD, Clore GM, (2007) Open-to-closed transition in apo 111. maltose-binding protein observed by paramagnetic NMR. Nature 449: 1078-1082.
111. James LC, Roversi P, Tawfik DS, (2003) Antibody multispecificity mediated by conformational diversity. Science 299: 1362-1367.
112. Marti-Renom MA, Stuart A, Fiser A, Sánchez R, Melo A, et al. (2000) Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct 29: 291-325.
113. Fiser A, Do RK, Sali A, (2000) Modeling of loops in protein structures. Protein Sci 9: 1753-1773.
114. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, et al. (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26: 1781-1802.
115. MacKerell AD Jr, Bashford D, Bellott M, Dunbrack RL Jr, Evanseck JD, et al. (1998) All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B 102: 3586-3616.
116. MacKerell AD Jr, Banavali N, Foloppe N, (2001) Development and current status of the CHARMM force field for nucleic acids. Biopolymers 56: 257-265.
117. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML, et al. (1983) Comparison of simple potential functions for simulating liquid water. J Chem Phys 79: 926-935.
118. Humphrey W, Dalke A, Schulten K, (1996) VMD: visual molecular dynamics. J Mol Graph 14:33-8, 27-28.
119. Eargle J, Wright D, Luthey-Schulten Z, (2006) Multiple alignment of protein structures and sequences for VMD. Bioinformatics 22: 504-506.
120. Dixit A, Verkhivker G, (2009) Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations PLoS Comput Biol 5: e1000487.
121. Dixit A, Verkhivker G, (2011) Computational modeling of allosteric communication reveals organizing principles of mutation-induced signaling in ABL and EGFR kinases. PLoS Comput Biol 7: e1002179.
122. Dixit A, Verkhivker G, (2011) The energy landscape analysis of cancer mutations. in protein kinases. PLoS One. 6: e26071.
123. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Res 28: 235-242.
124. Lovell SC, Word JM, Richardson JS, Richardson DC, (2000) The penultimate rotamer library. Proteins 40: 389-408.
125. Schaffer L, Verkhivker GM, (1998) Predicting structural effects in HIV-1 protease mutant complexes with flexible ligand docking and protein side-chain optimization. Proteins 33: 295-310.
126. Verkhivker GM, Bouzida D, Gehlhaar DK, Rejto PA, Freer ST, et al. (2002) Monte Carlo simulations of the peptide recognition at the consensus binding site of the constant fragment of human immunoglobulin G: the energy landscape analysis of a hot spot at the intermolecular interface. Proteins 48: 539-557.
127. Verkhivker GM, Bouzida D, Gehlhaar DK, Rejto PA, Freer ST, et al. (2003) Computational detection of the binding-site hot spot at the remodeled human growth hormone-receptor interface. Proteins 53: 201-219.
128. Mayo SL, Olafson BD, Goddard WA III, (1990) DREIDING: a generic force field for molecular simulation. J Phys Chem 94: 8897-8909.
129. Cornell WD, Cieplak P, Bayly CL, Gould IR, Merz KM, et al. (1995) A second generation force field for simulation of proteins, nucleic acids, and organic molecules. J Amer Chem Soc 117: 5179-5197.
130. Stouten PFW, Frommel C, Nakamura H, Sander C, (1993) An effective solvation term based on atomic occupancies for use in protein simulations. Mol Simul 10: 97-120.
131. Beutler TC, Mark AE, van Schaik RC, Gerber PR, van Gunsteren, W (1994) Avoiding singularities and numerical instabilities in free energy calculations base on molecular simulations. Chem Phys Lett 222: 529-539.
132. Marrone TJ, Luty BA, Rose PW, (2000) Discovering high-affinity ligands from the computationally predicted structures and affinities of small molecules bound to a target: A virtual screening approach. Perspect Drug Discovery Design 20: 209-223.
133. Wang J, Wolf RM, Caldwell JW, Kollman PA, Case DA, (2004) Development and testing of a general amber force field. J Comput Chem 25: 1157-1174.
134. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, et al. (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33: 889-897.
135. Onufriev A, Bashford D, Case DA, (2000) Modification of the Generalized Born Model suitable for macromolecules. J Phys Chem B 104: 3712-3720.
136. Bashford D, Case DA, (2000) Generalized born models of macromolecular solvation effects. Annu Rev Phys Chem 51: 129-152.
137. Homeyer N, Horn AH, Lanig H, Sticht H, (2006) AMBER force-field parameters for phosphorylated amino acids in different protonation states: phosphoserine, phosphothreonine, phosphotyrosine, and phosphohistidine. J Mol Model 12: 281-289.
138. Gilson MK, Zhou H-X, (2007) Calculation of protein-ligand binding affinities. Annu Rev Biophys Biomol Struct 36: 21-42.
139. Willet P, Winterman V, Bawden D, (1986) Implementation of non-hierarchical cluster analysis methods in chemical information systems: selection of compounds for biological testing and clustering of substructure search output. J Chem Inf Comput Sci 26: 109-118.